Nilofer Saba Azad, MD

home / authors / nilofer-saba-azad-md

Articles

Nilofer S​aba Azad, MD, of Johns Hopkins ​University School of Medicine

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

Nilofer Saba Azad, MD
October 30th 2020

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Read More

Nilofer S​aba Azad, MD, of Johns Hopkins Medicine

Dr. Azad on Third-Line Treatment Options in CRC

Nilofer Saba Azad, MD
October 29th 2020

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on Future Research Efforts in CRC

Nilofer Saba Azad, MD
October 21st 2020

Nilofer S​aba Azad, MD, discusses future research efforts in colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on the Importance of Germline Testing in CRC

Nilofer Saba Azad, MD
October 19th 2020

Nilofer S​aba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRC

Nilofer Saba Azad, MD
October 16th 2020

Nilofer S​aba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on Remaining Challenges in CRC

Nilofer Saba Azad, MD
October 15th 2020

Nilofer S​aba Azad, MD, discusses remaining challenges in colorectal cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need